Project Grant R01AA031217
- This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) provides $440,566 to Yale University to advance the treatment of alcohol-associated liver disease (ALD). The primary objective is to uncover therapeutic targets and develop effective ALD treatments, with a focus on the methyltransferase-like (METTL) protein family, notably METTL7A, which is highly expressed in ALD patients. The research utilizes cutting-edge technology...
- This $177,736 Project Grant award was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) located in Massachusetts. The project aims to investigate the role of hepatokines, predominantly hepatocyte-secreted proteins, in the pathogenesis of alcohol-associated liver disease and alcohol-associated hepatitis. Specifically, the research will explore the involvement of the...
- This federal Project Grant award of $701,051 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The grant supports research to investigate the phenotypes and functions of distinct neutrophil populations in patients with severe alcohol-associated hepatitis (AH). Key objectives include: 1) Characterizing the transcriptomic profiles and functional roles of neutrophil subsets in AH using single-cell RNA sequencing; 2)...
- This Project Grant award of $123,045.00 from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) supports research on the role of the TRAF3IP2 protein in the development of alcohol-related cardiomyopathy. The project will investigate whether alcohol-induced cardiac fibroblast activation, proinflammatory cytokine expression, and extracellular matrix changes are dependent on TRAF3IP2, and whether deleting the TRAF3IP2 gene prevents alcohol-induced...
- This Project Grant award of $639,177.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support research to investigate the role of hepatic FOXA3 in the development and progression of alcohol-associated liver disease (ALD). The University of Arizona will conduct this research project to gain a better understanding of the mechanisms underlying the pathogenesis of ALD, which is the most prevalent...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $3,168,729 to New York University to conduct a collaborative research project titled "A Translational Approach for Novel Precision Medicine Models." The project aims to identify novel molecular targets and mechanisms of treatment responses in alcohol use disorder (AUD) based on the role of mitochondrial metabolism and epigenetic...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (ALD). This research aims to investigate the liver-specific effects of the inflammasome, a key mediator of inflammation, in hepatocytes - the predominant liver cell type and a driver of ALD pathophysiology. The project will use mouse models to evaluate...
- The federal Project Grant award titled "Role of Functional Iron Deficiency in Alcohol-Associated Liver Disease" is funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The $390,480 award, effective from September 10, 2025 to August 31, 2027, will support research at Emory University to investigate the molecular mechanisms underlying alcohol-associated mitochondrial dysfunction and its role in the progression of...
- This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs), supports research to determine the molecular mechanism by which the neutrophilic NCF1 gene and its downstream target miR-223 impact the pathogenesis of alcohol-associated liver disease (ALD). The $249,000 project, awarded to the Trustees of Indiana University, will investigate how neutrophils drive disease severity and mediate liver injury in ALD through the...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,376,398 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to develop a humanized mouse model to study alcohol-associated hepatitis (AAH). The project aims to create a fully humanized mouse liver system by engrafting human hepatocytes and non-parenchymal cells to better understand the complex cell interactions that drive key features of AAH, a leading cause of liver-related deaths...
This federal Project Grant award of $659,865 from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) supports research at Yale University to investigate the role of aberrant mitochondrial calcium signaling in the development of alcohol-associated hepatitis (AAH). The project will examine how the expression and localization of the inositol trisphosphate receptor (ITPR) isoforms, particularly ITPR3, impact mitochondrial calcium signals and cellular metabolism in hepatocytes during the progression of AAH. The award, with a start date of September 16, 2025 and an ultimate completion date of July 31, 2030, aims to improve understanding of the pathophysiological mechanisms underlying this severe and potentially life-threatening complication of alcohol-associated liver disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $659.9k | 9/16/25 |